For complete control over gene update notifications, ClinGen recommends you login or create an account. If you select "Remember Me" during login, ClinGen will remember your login until you manually log out.

If you cannot login at this time, enter your email address and click on submit. You will not have access to your dashboard, however, ClinGen will save your requests pending confirmationo of your email address.

Email:
Cancel Login

Follow Gene

Gene Facts External Data Attribution

HGNC Symbol
RELB (HGNC:9956) HGNC Entrez Ensembl OMIM UCSC Uniprot GeneReviews LOVD LSDB ClinVar
HGNC Name
RELB proto-oncogene, NF-kB subunit
Gene type
protein-coding gene
Locus type
gene with protein product
Previous symbols
No previous names found
Alias symbols
REL-B
GenCC Classifications
Limited2 (Read more about GenCC Classifications)
%HI
38.34(Read more about the DECIPHER Haploinsufficiency Index)
pLI
0.97(Read more about gnomAD v4.0 pLI score)
LOEUF
0.51(Read more about gnomAD v4.0 LOEUF score)
pLI and LOEUF metrics based on ENST00000221452 transcript
ACMG SF v3.2 Gene?
No
Cytoband
19q13.32
Genomic Coordinates
GRCh37/hg19: chr19:45504722-45541450 NCBI Ensembl UCSC
GRCh38/hg38: chr19:45001464-45038192 NCBI Ensembl UCSC
MANE Select Transcript
NM_006509.4 ENST00000221452.13 (Read more about MANE Select)
Function
NF-kappa-B is a pleiotropic transcription factor which is present in almost all cell types and is involved in many biological processed such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences ... (Source: Uniprot)
Gene Disease MOI Expert Panel Classification Report & Date
RELB
immunodeficiency 53
MONDO:0054696
AR SCID-CID GCEP Limited 03/30/2023
Lumping and Splitting is the process by which ClinGen curation groups determine which disease entity they will use for evaluation. Groups review current disease and/or phenotype assertions (e.g. OMIM MIM phenotypes) and select the included and excluded phenotypes according to current guidelines. MIM phenotypes represented below are those that were available on the stated evaluation date.
Included MIM Phenotypes :
Excluded MIM Phenotypes :
No Excluded MIM Phenotypes were specified
Evaluation Date :
03/30/2023
Curation Type :
Curate a single gene-disease entity from this list (Read more about curation type)
Rationales :
Insufficient evidence to support multiple distinct diseases at this time (Read more about curation type)
PMIDs :
No PMIDs were specified
Notes :
No Notes were specified
Expert Panel:
No Secondary Contributors were specified
History:
None
Other Stuff:
Lorem Epsum